Whether you're joining us in May in Venice or somewhere else in the world online, we've got you covered. Novo Nordisk is committed to delivering the best hybrid experience for healthcare professionals by combining our engaging and interactive booth with our online presence on CongressHub.
ECO2024 will feature Novo Nordisk's cutting-edge obesity offerings, including innovative digital solutions, scientific content, and networking with the joining healthcare professionals.
Wegovy® (semaglutide injection 2.4 mg) is the first once-weekly GLP-1 RA* indicated for weight management, helping your patients obtain a 16.7% (17.6 kg) mean weight loss sustained over 2 years.**1-2
*GLP-1 RA, glucagon-like peptide-1 receptor agonist.
**At 104 weeks, mean weight loss was 16.7% vs. 0.6% with placebo in the STEP 5 trial2
Wegovy® (semaglutide injection 2.4 mg) is the first once-weekly GLP-1 RA* indicated for weight management, helping your patients obtain a 16.7% (17.6 kg) mean weight loss sustained over 2 years.**1-2
*GLP-1 RA, glucagon-like peptide-1 receptor agonist.
**At 104 weeks, mean weight loss was 16.7% vs. 0.6% with placebo in the STEP 5 trial2
